Stay updated on Pembrolizumab for Rare Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Rare Tumors Clinical Trial page.

Latest updates to the Pembrolizumab for Rare Tumors Clinical Trial page
- Check7 days agoChange DetectedRevision tag updated from v3.6.4 to v3.6.5, indicating a new build or patch of the site or documentation rather than a change to study details.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe revision tag was updated from v3.6.3 to v3.6.4. This appears to be a minor software update with no evident changes to content or user-facing features in the provided context.SummaryDifference0.0%

- Check28 days agoChange DetectedThe page's update dates were refreshed in July 2026, replacing earlier January 2026 timestamps. This reflects routine maintenance to keep the study record's metadata current.SummaryDifference0.2%

- Check43 days agoChange DetectedThe page now displays a new revision tag, Revision: v3.6.3, replacing the previous v3.6.2. This indicates a new build of the page content without changing the study details themselves.SummaryDifference0.0%

- Check50 days agoChange DetectedA new publication citation by Derbala et al. was added to the study's Publications, documenting AI-guided analysis predicting pembrolizumab response in rare tumors. The page revision was updated to v3.6.2, replacing the previous v3.6.0.SummaryDifference0.1%

- Check64 days agoChange DetectedAdded user guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) and a recruitment status note ('No longer looking for participants'), reflecting a change in participant availability. Updated the Interventions label from 'Intervention / Treatment' to 'Intervention/Treatment' and added a new revision (Revision: v3.6.0) while removing the older label (Revision: v3.5.5).SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab for Rare Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Rare Tumors Clinical Trial page.